So-called 'functional cure' to HIV makes way into human trials

December 1, 2016 07:26


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

A surprising study in monkeys involving an antibody used to treat Crohn's disease has raised new hopes for a so-called "functional cure" for HIV - treatments that put their disease in sustained remission - allowing patients to skip the daily cocktail of pills they must take to keep their disease in check.

The study came out of the lab of Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Disease in Bethesda, who is now presiding over a clinical trial testing whether the drug, made by Japanese drug maker Takeda, can control HIV without the need for ongoing treatment.

Related Content

Breaking news
August 18, 2018
U.N. chief suggests options for improved Palestinian protection